targeting

Itch-Targeting Compound 1 is an anti-itch agent effective in preventing or treating reactions from insect bites, environmental allergens, skin infections, external vermination, or itching in renal dialysis patients.

Cancer-Targeting Compound 1 can be used in the study of hormone-related cancers, including the treatment or prevention of fibroids, uterine leiomyomas, polycystic ovarian syndrome, or hormone-dependent Cancer, among others.

Neuromuscular-targeting compound 1 can be used to study muscular dystrophy and neuromuscular-related diseases.

FAP targeting peptide for FXX489 is the peptide component of FXX489. FXX489 is a targeting ligand that can specifically recognize and bind to fibroblast activation protein (FAP).

FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα), exhibiting specific binding capabilities to cells expressing FRα and potential for in vivo tumor targeting. This peptide is utilized in research for tumor diagnosis and therapy.

(Rac)-Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor.

GPC3 targeting peptide 1 binds to GPC3 with a dissociation constant (Kd) of 0.23 nM.

G3BP1 2-Targeting ligand-1 is a ligand for G3BP1 2 and can be utilized as a targeting ligand in the synthesis of the G3BP1 2 PROTAC degrader PT-129.

Breastcancertargeting peptide 18–4 is a keratin 1 (KRT1) receptor-targeting peptide with a dissociation constant (Kd) of 0.98 μM. Its amino acid sequence is WxEAAYQrFL, and it is an analogue of the P160 peptide. When covalently bonded with the anticancer peptide MccJ25, it significantly enhances MccJ25 uptake in breast cancer cells and boosts its anticancer efficacy. The IC50 values for this covalent compound are 14.2, 20, and 25 μM against MCF-7, MDA-MB-435, and MDA-MB-435-MDR, respectively.

Urinary Incontinence-Targeting Compound 1, used in the research of urinary incontinence, is a sulfonanilide derivative.

Arrhythmias-Targeting Compound 1 is a compound. It is used in the research of arrhythmias.

Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor [1].

Peptide 46 is a short peptide that inhibits SC-dependent DNA synthesis by targeting the bacterial sliding clamp (SC).

Neuromuscular Disorder-Targeting Compound 1 is utilized in research for neuromuscular disorders, including chronic fatigue syndrome and fibromyalgia syndrome symptoms.

dTAG Targeting Ligand 1 (SUBSTITUTE SHEET 245) serves as a ligand for target proteins in PROTAC (Proteolysis Targeting Chimera) applications. It is used in the synthesis of PROTACs.

Arrhythmic-Targeting Compound 1, used for arrhythmic disease, contains nitrogen-containing spirocycles.

VVD-130037 is a small molecule activator specifically targeting Kelch-like ECH-associated protein 1 (KEAP1) with potential antitumor activity.VVD-130037 inhibits tumor growth in advanced solid tumors by degrading NRF2.

Eribulin mesylate (E7389 mesylate) (E7389 mesylate) inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used in the treatment of metastatic breast cancer.

Tezepelumab (AMG 157) is a humanized monoclonal antibody (IgG2λ) targeting TSLP that prevents TSLP from interacting with its heterodimer receptor. Tezepelumab can be used to study advanced asthma disease.

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3 1 1 4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.

Dxd (OQM5SD32BQ) is a potent inhibitor of DNA topoisomerase I with an IC50 of 0.31 μM. It is used as a conjugated drug of HER2-targeting ADC.

Brentuximab, a chimeric antibody targeting CD30, is a naked antibody to Brentuximab vedotin. It possesses antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.

Avapritinib (BLU-285) is a selective, highly potent, and orally active inhibitor of KIT and PDGFRA activation loop mutant kinases, targeting KIT D816V (IC50:0.27 nM) and PDGFRA D842V (IC50:0.24 nM), and attenuates the transport functions of ABCB1 and ABCG2. It binds to the active conformation of the kinases and exhibits antitumor activity.